Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT Analysis Review

GlobalData, September 2011, Pages: 41

Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT Analysis Review

Summary

Ardea Biosciences, Inc. (Ardea Biosciences) is a biotechnology company principally engaged in the discovery and development of therapeutics moleculefor the treatment of HIV, gout, cancer and inflammatory diseases. Ardea Biosciences principally focuses on in development of antimicrobial drugs. Its lead product candidate, Lesinurad formerly known as RDEA594 has completed Phase 2 clinical development and is being developed for the treatment of hyperuricemia and gout. Ardea Biosciences has intellectual property base acquired from Valeant Research and Development, Inc. for the development of products. Ardea Biosciences is headquartered in California, the US.

Ardea Biosciences, Inc. Key Recent Developments

Aug 05, 2011 Ardea Biosciences Reports Total Revenue Of $2.2m For Q2 2011
May 09, 2011 Ardea Biosciences Reports Net Loss Of $15.2m For Q1 2011
Apr 25, 2011 Ardea Biosciences To Present Additional Data From Completed Phase IIb Combination Study Of Lesinurad At Annual European Congress Of Rheumatology
Mar 11, 2011 Ardea Biosciences Reports Revenues Of $17.3m For Q4 2010
Nov 09, 2010 Ardea Biosciences Reports Net Loss Of $18.2m For Q3 2010

This comprehensive SWOT profile of Ardea Biosciences, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

List of Tables
List of Figures
Section 1 - About the Company
Ardea Biosciences, Inc. - Key Facts
Ardea Biosciences, Inc. - Key Employees
Ardea Biosciences, Inc. - Key Employee Biographies
Ardea Biosciences, Inc. - Major Products and Services
Ardea Biosciences, Inc. - Pharmaceutical Pipeline Products Data
Ardea Biosciences, Inc., Pipeline Products by Therapy Area
Ardea Biosciences, Inc., Pipeline Products by Development Phase
Ardea Biosciences, Inc. - History
Ardea Biosciences, Inc. - Company Statement
Ardea Biosciences, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Ardea Biosciences, Inc. - Business Description
Ardea Biosciences, Inc. - SWOT Analysis
SWOT Analysis - Overview
Ardea Biosciences, Inc. - Strengths
Strength - Focused Research and Development
Strength - Strong Patent Portfolio
Strength - Global Agreement with Bayer HealthCare
Strength - Expanding Liquidity Position
Weakness - Geographical Concentration
Weakness - Decreased Efficiency
Weakness - Lack of Internal Manufacturing Capabilities
Opportunity - Market Potential: HIV
Opportunity - Growing Oncology Treatment Market
Opportunity - Targeting the Treatments for Gout
Opportunity - Positive Clinical Results
Threat - Tightening of FDA’s Regulatory Oversight
Threat - Competitive Pressures
Threat - Lack of Marketable Products
Ardea Biosciences, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Ardea Biosciences, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 05, 2011: Ardea Biosciences Reports Total Revenue Of $2.2m For Q2 2011
May 09, 2011: Ardea Biosciences Reports Net Loss Of $15.2m For Q1 2011
Apr 25, 2011: Ardea Biosciences To Present Additional Data From Completed Phase IIb Combination Study Of Lesinurad At Annual European Congress Of Rheumatology
Mar 11, 2011: Ardea Biosciences Reports Revenues Of $17.3m For Q4 2010
Nov 09, 2010: Ardea Biosciences Reports Net Loss Of $18.2m For Q3 2010
Nov 02, 2010: Ardea Biosciences Receives $733,438 Grant From US Government Under Patient Protection And Affordable Care Act
Aug 06, 2010: Ardea Biosciences Reports Net Loss Of $12.8 Million For Q2 2010
Jun 18, 2010: Positive Phase 2 Data On Rdea594, Ardea Biosciences Lead Product Candidate For The Treatment Of Hyperuricemia And Gout, Presented At The Annual European Congress Of Rheumatology
May 07, 2010: Ardea Reports Net Loss Of $10 Million For Q1 2010
Apr 12, 2010: Ardea Biosciences Names Stephen Davis As Executive Vice President And COO
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ardea Biosciences, Inc., Key Facts
Ardea Biosciences, Inc., Key Employees
Ardea Biosciences, Inc., Key Employee Biographies
Ardea Biosciences, Inc., Major Products and Services
Ardea Biosciences, Inc., Number of Pipeline Products by Therapy Area
Ardea Biosciences, Inc., Number of Pipeline Products by Development Stage
Ardea Biosciences, Inc., Pipeline Products By Therapy Area and Development Phase
Ardea Biosciences, Inc., History
Ardea Biosciences, Inc., Subsidiaries
Ardea Biosciences, Inc., Key Competitors
Ardea Biosciences, Inc., Ratios based on current share price
Ardea Biosciences, Inc., Annual Ratios
Ardea Biosciences, Inc., Interim Ratios
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Ardea Biosciences, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Ardea Biosciences, Inc., Pipeline Products by Therapy Area
Ardea Biosciences, Inc., Pipeline Products by Development Phase
Ardea Biosciences, Inc., Performance Chart (2006 - 2010)
Ardea Biosciences, Inc., Ratio Charts
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011

Vertex Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Insmed Incorporated
XOMA Ltd.
Idenix Pharmaceuticals, Inc.
Array BioPharma Inc.

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile